Stockreport

Syros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AML

Syros Pharmaceuticals, Inc.  (SYRS) 
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am Check Earnings Report
US:NASDAQ Investor Relations: ir.syros.com
PDF Data Show Significant Correlation Between Biomarker Status of Patients Screened for the Clinical Trial and Myeloid Differentiation of Patient Blood Cells [Read more]